Literature DB >> 10434300

Properties of polyglutamine expansion in vitro and in a cellular model for Huntington's disease.

A Lunkes1, Y Trottier, J Fagart, P Schultz, G Zeder-Lutz, D Moras, J L Mandel.   

Abstract

Eight neurodegenerative diseases have been shown to be caused by the expansion of a polyglutamine stretch in specific target proteins that lead to a gain in toxic property. Most of these diseases have some features in common. A pathological threshold of 35-40 glutamine residues is observed in five of the diseases. The mutated proteins (or a polyglutamine-containing subfragment) form ubiquitinated aggregates in neurons of patients or mouse models, in most cases within the nucleus. We summarize the properties of a monoclonal antibody that recognizes specifically, in a Western blot, polyglutamine stretches longer than 35 glutamine residues with an affinity that increases with polyglutamine length. This indicates that the pathological threshold observed in five diseases corresponds to a conformational change creating a pathological epitope, most probably involved in the aggregation property of the carrier protein. We also show that a fragment of a normal protein carrying 38 glutamine residues is able to aggregate into regular fibrils in vitro. Finally, we present a cellular model in which the induced expression of a mutated full-length huntingtin protein leads to the formation of nuclear inclusions that share many characteristics with those observed in patients: those inclusions are ubiquitinated and contain only an N-terminal fragment of huntingtin. This model should thus be useful in studying a processing step that is likely to be important in the pathogenicity of mutated huntingtin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10434300      PMCID: PMC1692598          DOI: 10.1098/rstb.1999.0453

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  34 in total

1.  Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors.

Authors: 
Journal:  Curr Opin Biotechnol       Date:  1997-02-01       Impact factor: 9.740

2.  Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates.

Authors:  D Martindale; A Hackam; A Wieczorek; L Ellerby; C Wellington; K McCutcheon; R Singaraja; P Kazemi-Esfarjani; R Devon; S U Kim; D E Bredesen; F Tufaro; M R Hayden
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

3.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

Authors:  M DiFiglia; E Sapp; K O Chase; S W Davies; G P Bates; J P Vonsattel; N Aronin
Journal:  Science       Date:  1997-09-26       Impact factor: 47.728

4.  Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.

Authors:  L Mangiarini; K Sathasivam; M Seller; B Cozens; A Harper; C Hetherington; M Lawton; Y Trottier; H Lehrach; S W Davies; G P Bates
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

5.  Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo.

Authors:  E Scherzinger; R Lurz; M Turmaine; L Mangiarini; B Hollenbach; R Hasenbank; G P Bates; S W Davies; H Lehrach; E E Wanker
Journal:  Cell       Date:  1997-08-08       Impact factor: 41.582

6.  Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias.

Authors:  Y Trottier; Y Lutz; G Stevanin; G Imbert; D Devys; G Cancel; F Saudou; C Weber; G David; L Tora
Journal:  Nature       Date:  1995-11-23       Impact factor: 49.962

7.  Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases.

Authors:  M F Perutz; T Johnson; M Suzuki; J T Finch
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

8.  Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.

Authors:  F Saudou; S Finkbeiner; D Devys; M E Greenberg
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

9.  Synapse formation between clonal neuroblastoma X glioma hybrid cells and striated muscle cells.

Authors:  P Nelson; C Christian; M Nirenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1976-01       Impact factor: 11.205

10.  "Cryptic" repeating triplets of purines and pyrimidines (cRRY(i)) are frequent and polymorphic: analysis of coding cRRY(i) in the proopiomelanocortin (POMC) and TATA-binding protein (TBP) genes.

Authors:  B Gostout; Q Liu; S S Sommer
Journal:  Am J Hum Genet       Date:  1993-06       Impact factor: 11.025

View more
  4 in total

1.  Side-chain interactions determine amyloid formation by model polyglutamine peptides in molecular dynamics simulations.

Authors:  Alexander J Marchut; Carol K Hall
Journal:  Biophys J       Date:  2006-03-24       Impact factor: 4.033

2.  Location trumps length: polyglutamine-mediated changes in folding and aggregation of a host protein.

Authors:  Matthew D Tobelmann; Regina M Murphy
Journal:  Biophys J       Date:  2011-06-08       Impact factor: 4.033

Review 3.  Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives.

Authors:  J J Magaña; L Velázquez-Pérez; B Cisneros
Journal:  Mol Neurobiol       Date:  2012-09-21       Impact factor: 5.590

4.  Polyglutamine expansion mutation yields a pathological epitope linked to nucleation of protein aggregate: determinant of Huntington's disease onset.

Authors:  Keizo Sugaya; Shiro Matsubara; Yasuhiro Kagamihara; Akihiro Kawata; Hideaki Hayashi
Journal:  PLoS One       Date:  2007-07-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.